Benedetta Pellegrino

A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation

Marta Castroviejo‐Bermejo, Cristina Cruz, Alba Llop‐Guevara et al. · EMBO Molecular Medicine · 2018 · 274 citations · Full text

Medicine, Cancer Biology, Oncology +9

Preclinical <i>In Vivo</i> Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification

Benedetta Pellegrino, Andrea Herencia-Ropero, Alba Llop‐Guevara et al. · Cancer Research · 2022 · 97 citations · Full text

Medicine, Genetics, Oncology +15

Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study

Marina Elena Cazzaniga, G. Pinotti, Emilia Montagna et al. · The Breast · 2019 · 57 citations

Medicine, Oncology, Breast Oncology +9

Genetic Basis of Breast and Ovarian Cancer: Approaches and Lessons Learnt from Three Decades of Inherited Predisposition Testing

Valeria Barili, Enrico Ambrosini, Beatrice Bortesi et al. · Genes · 2024 · 47 citations · Full text

Life Sciences, Genetics, Oncology +17

Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial

Ettore Capoluongo, Benedetta Pellegrino, Laura Arenare et al. · ESMO Open · 2022 · 43 citations · Full text

Medicine, Molecular Biology, Oncology +16